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Abstract
Background: The identification of antigens able to differentiate tuberculosis (TB) disease from TB
infection would be valuable. Cellular and humoral immune responses to Erp (Exported repetitive
protein) – a recently identified M. tuberculosis protein – have not yet been investigated in humans
and may contribute to this aim.
Methods: We analyzed the cellular and humoral immune responses to Erp, ESAT-6, Ag85B and
PPD in TB patients, in BCG+ individuals without infection, BCG+ individuals with latent TB infection
(LTBI) and BCG- controls. We used lymphoproliferation, ELISpot IFN-γ, cytokine production
assays and detection of specific human antibodies against recombinant M. tuberculosis proteins.
Results: We included 22 TB patients, 9 BCG+ individuals without TB infection, 7 LTBI and 7 BCG-
controls. Erp-specific T cell counts were higher in LTBI than in the other groups. Erp-specific T cell
counts were higher in LTBI subjects than TB patients (median positive frequency of 211 SFC/106
PBMC (range 118–2000) for LTBI subjects compared to 80 SFC/106 PBMC (range 50–191), p =
0.019); responses to PPD and ESAT-6 antigens did not differ between these groups. IFN-γ secretion
after Erp stimulation differed between TB patients and LTBI subjects (p = 0.02). Moreover, LTBI
subjects but not TB patients or healthy subjects produced IgG3 against Erp.
Conclusion: The frequencies of IFN-γ-producing specific T cells, the IFN-γ secretion and the
production of IgG3 after Erp stimulation are higher in LTBI subjects than in TB patients, whereas
PPD and ESAT-6 are not.
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Background
Tuberculosis (TB) remains a major public health problem.
It is estimated that one third of the world's population has
latent Mycobacterium tuberculosis infection [1]. Vaccination
with Bacillus of Calmette-Guérin (BCG) confers only par-
tial protection. The protective immune responses elicited
by tuberculosis infection or vaccination with BCG in non
endemic countries remain poorly understood. After infec-
tion, activated macrophages produce interleukin (IL)-12,
which in turn stimulates CD4 T cells to produce Th1
cytokines (IFN-γ and TNF-α), thus linking the innate and
adaptive immune responses [2,3]. Th1 cellular responses
are essential for effective protection against TB in several
animal models. Although the immune responses induced
by TB are generally able to contain the pathogen, they are
unable to eliminate it, and 5 to 10% of immunocompe-
tent individuals develop tuberculosis [2,4].
Many studies have investigated immune responses in TB
patients and healthy contacts. As BCG vaccination is
widely used in countries with a high incidence of tubercu-
losis, we decided to use a new M. tuberculosis antigen, Erp,
to analyze cellular and humoral immune responses in TB
patients and in healthy individuals, including both those
who had or had not been vaccinated with BCG. In
infected humans and animal models, both surface and
secreted antigens such as ESAT-6, Ag85B antigens and
heparin-binding hemagglutinin adhesin, have been iden-
tified as inducers of Th1 CD4 cellular immune responses
[5-9]. Erp is (Exported repetitive protein), is an antigen
exported by Mycobacterium species [10-12]. The Erp gene
encodes a cell-surface component with a repetitive struc-
ture [11,13,14]. Erp is present in all strains of mycobacte-
ria, including BCG strains, but its sequence varies (12). It
is required for the survival and multiplication of myco-
bacteria [10,15]. Homologs of this antigen are immuno-
dominant in both lepromatous leprosy and bovine
tuberculosis [15,16]. Cellular and humoral immune
responses against this antigen have not been investigated
in humans and only animal studies are available.
ESAT-6 is an early-secreted antigen, encoded by the RD-1
genetic region. This region is absent, presumably deleted,
from M. bovis BCG strains and in environmental mycobac-
teria [17-19]. T cell responses to ESAT-6 differ between TB
patients and healthy BCG-vaccinated controls and can be
used to identify symptom-free individuals recently
exposed to M. tuberculosis [20-25]. Ag85B, which belongs
to the 85 complex including 85A, B and C antigens, is
involved in the final stages of the cell wall synthesis
[26,27]. This antigen complex induces strong Th1 cellular
immune responses in PPD-positive healthy individuals,
but weak responses in 50% of TB patients [28,29]. More-
over, inclusion of Ag85A or Ag85B in a protein or DNA
vaccine confers significant protection against tuberculosis
in mice [30,31]. We studied and compared specific cellu-
lar and humoral immune responses to Erp, an antigen of
latency, with those to ESAT-6, Ag85B, 2 antigens involved
in the virulence of the mycobacteria and PPD as compar-
ison in TB patients and in individuals vaccinated (healthy
and latent TB) or not vaccinated with BCG.
Immune responses against Erp were detected in TB
patients and in BCG+ individuals both without infection
and with latent TB infection (LTBI). The frequencies of
IFN-γ-producing specific T cells, the IFN-γ secretion and
the production of IgG3 were higher in BCG+ subjects with
LTBI after Erp stimulation. This pilot study suggests that
Erp-specific responses may be a valuable marker to distin-
guish LTBI from TB subjects, and should be evaluated in
larger studies.
Methods
Patients
This prospective study was carried out in the Department
of Infectious Diseases of Pitié-Salpêtrière Hospital and in
the Department of Internal Medicine of Lariboisière Hos-
pital, Paris, France, between February 2001 and February
2002. The study protocol was approved by the institu-
tional review board of Pitié-Salpêtrière Hospital and was
carried out in accordance with the Declaration of Hel-
sinki.
We recruited twenty-two TB patients, according to the fol-
lowing criteria: ≥18 years old, and with microbiologically
confirmed TB disease; patients who had already begun
treatment were excluded from the study. All subjects were
counselled about HIV testing and provided written
informed consent.
Sixteen BCG-vaccinated individuals (BCG+) were
enrolled, according to the following inclusion criteria:
≥18 years old, with prior BCG vaccination and no
reported or known history of TB infection or disease. This
group was divided into two sub-groups: those giving at
least one positive response to ESAT-6 in at least one of the
three tests used (lymphoproliferation, ELISpot IFN-γ,
cytokine production assays) and those scoring negative in
all tests. Nine subjects gave no positive responses and
were considered as uninfected (BCG+ without infection
group) and seven displayed positive responses to ESAT-6
and were considered to have latent TB infection (LTBI).
For comparison, seven healthy non-BCG-vaccinated
(BCG-) individuals were enrolled, according to the follow-
ing criteria: ≥18 years old, no prior BCG vaccination and
no history of TB exposure or infection. This last control
group was recruited by the Departments of Infectious Dis-
eases, of Immunohematology and Blood Transfusion of
Leiden University Medical Center (Leiden, Netherlands).BMC Infectious Diseases 2007, 7:83 http://www.biomedcentral.com/1471-2334/7/83
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Preparation of peripheral blood mononuclear cells
Venous blood (40 ml) from each participant was collected
into heparin. Peripheral blood mononuclear cells
(PBMC) were prepared by Ficoll-Hypaque centrifugation
(Eurobio) of the blood.
CD4+ T-cell purification
CD4+ T cells were purified from PBMC by magnetic sepa-
ration, using a Dynabeads kit according to the manufac-
turer's instructions (Dynabeads, Dynal, Oslo, Norway).
The purity of the CD8-depleted cells was analyzed by flow
cytometry and exceeded 95%. CD8 cells accounted for less
than 5% of the remaining cells.
Antigens
A purified protein derivative of Mycobacterium tuberculosis
(PPD) (Statens Serum Institute, Copenhagen, Denmark)
was used at a concentration of 1 μg/ml as is routine in our
laboratory. ESAT-6 was a gift from the Statens Serum Insti-
tute (Copenhagen, Denmark) and was used at a concen-
tration of 1 μg/ml. Antigen Ag85B was obtained from
Lionex Diagnostics and Therapeutics GmbH (Braunsch-
weig, Germany) and was used at a concentration of 2 μg/
ml. Erp produced as a recombinant antigen in Escherichia
coli M15, purified by Aventis Pasteur SA (Marcy L'Etoile,
France), was used at a concentration of 0.5 μg/ml. Antigen
preparations were tested for LPS contamination: ESAT-6
was free of LPS, and Ag85B and Erp contained less than
100 EU/mg of endotoxin. Concentrations of ESAT-6, Erp
and Ag85B were defined by testing a large dilution series
of antigen concentrations in a population of tuberculosis
patients (n = 12) and the optimal concentration of each
antigen was selected.
Evaluation of specific T-cell responses
Lymphoproliferation assay
The lymphoproliferation assay was carried out with
freshly isolated PBMC from TB patients and BCG+ con-
trols. PBMC (1.5 × 105) were cultured in 200 μl of com-
plete medium in round-bottomed microtiter tissue
culture plates (TPP®, Switzerland), with or without each of
the antigens. We assessed the stimulation activity of all
antigens. Phytohemagglutin was used as a positive control
(PHA, Murex, Paris, France), at a concentration of 0.5 μg/
ml. Medium alone was used as a negative control. Cells
were cultured in complete medium (RPMI 1640 supple-
mented with 1% essential amino acids, 1% sodium pyru-
vate, 25 × 103 U penicillin and 25 × 103 μg streptomycin)
(GibcoBRL), together with 20% pooled, HIV-free, male
human AB serum (AbCys, Paris, France). Cells were incu-
bated alone or with one of the antigens, for 6 days at
37°C, in a humidified atmosphere containing 5% CO2.
Cells were then labeled with tritiated thymidine (CEA,
Saclay, France) on day 6. Cells were harvested on fiber-
glass paper, using a cell harvester (Printed Filtermat A,
Wallac Oy, Finland), and the incorporated radioactivity
was measured in a liquid scintillation counter
(Microbeta™ Plus, Wallac). Mean counts per minute for
triplicate cultures and a stimulation index (SI) were
obtained for each patient. The SI was the ratio of mean
counts per minute in the presence of antigen to mean
counts per minute in medium alone. Antigen-specific pro-
liferative responses were considered to be positive if SI ≥ 3.
ELISpot-IFN-γ assay
The ELISpot IFN-γ assay was carried out with freshly pre-
pared PBMC from TB patients and BCG+ subjects and with
frozen cells from BCG- individuals.
The anti-human IFN-γ capture Mab (Diaclone) was used
to coat 96-well polyvinylidene difluoride plates (Milli-
pore, Molsheim, France), by incubation overnight at 4°C.
Each of the various antigens (Erp, ESAT-6, Ag85B and
PPD) was added to three wells (triplicate), at the concen-
trations indicated above. PBMC were cultured in complete
medium (see above) supplemented with fetal calf serum
(10%, Gibco, France). Negative controls consisted of cells
cultured with medium alone and positive controls con-
sisted of cells cultured with PHA. PBMC (1.5 × 105 per
well corresponding to the number of cells inducing opti-
mal responses to these antigens) were incubated for 40
hours at 37°C in an atmosphere containing 5% CO2, as
previously described [32]. The plates were washed and a
biotinylated anti-IFN-γ Mab (Diaclone) was added, fol-
lowed by streptavidin-alkaline phosphatase conjugate
(Amersham, Les Ulis, France) and chromogen substrates
(5-bromo-4-chloro-3-indolyl phosphate toluidine and
nitroblue tetrazolium) (Sigma-Aldrich, St. Quentin,
France). Plates were dried and the colored spots were
counted using an automated ELISpot reader (Zeiss, Jena,
Germany). The numbers of specific T cells are expressed as
spot-forming cells per million PBMC (SFC/106 PBMC),
calculated after subtracting the mean values obtained
without antigen for each sample. Responses were consid-
ered positive if the test well contained at least 5 IFN-γ SFC
more than negative control wells.
Cytokine production
Cytokine production was assessed in freshly prepared
cells from TB patients and BCG+ controls. Freshly pre-
pared PBMC (1.5 × 105) were cultured in 96-well flat-bot-
tomed plates (TPP®, Switzerland) with the antigens Erp,
ESAT-6, Ag85B and PPD. The negative control consisted
of medium alone and the positive control included anti-
CD3 (2.5 μg/ml) and anti-CD28 antibodies (5 μg/ml;
Immunotech, Coulter, France). Supernatants (150 μl)
were collected after 48 hours and frozen at -20°C. The fro-
zen supernatants were thawed at room temperature and
cytokine concentrations were determined, using a com-
mercial kit designed to detect multiple human Th1/Th2BMC Infectious Diseases 2007, 7:83 http://www.biomedcentral.com/1471-2334/7/83
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cytokines (IFN-γ, TNF-α, IL-2, IL-4, IL-5 and IL-10) in a
single sample, in accordance with the manufacturer's
instructions (Cytometric Bead Array Kit, BD Pharmingen).
The Cytometric Bead Array (CBA) is a flow cytometric-
based assay for the detection of human cytokines from
cell supernatants or serum samples. The kit uses a set of
beads coated with cytokine-specific antibodies which
serves as a capture surface for cytokines; we used the 6
bead kit, which includes beads specific for IFN-γ, TNF-α,
IL-2, IL-10, IL-4, IL-5. Each cytokine-specific set of beads
is assigned a discrete fluorescence intensity that can be
resolved on the FL-3 channel of a flow cytometer. The
advantage of using the CBA assay is that it is an accurate,
sensitive and quantitative method for measuring cytokine
levels although requiring only small volumes for analysis.
The detection limit of the assay was 50 pg/ml. The values
obtained for the negative control (unstimulated) wells
were subtracted from those obtained with stimulated cells
and the results are expressed in pg/ml.
Elisa test for detection of specific human antibodies against 
recombinant M. tuberculosis proteins
Serum samples from a subgroup of 15 of the 22 TB
patients, seven BCG+ subjects and six BCG- controls were
available for testing. Dynatech®  96-well flat-bottomed
plates (Dynex Technologie, France) were coated by incu-
bation overnight with 50 μl/well of the recombinant pro-
teins (Erp, ESAT-6, Ag85B) at a concentration of 3 μg/ml
in phosphate-buffered saline (PBS). PBS was used as a
negative control. Plates were blocked by incubation with
3% bovine serum albumin (BSA) (Prolabo, Fontenay-
sous-Bois, France) in PBS, for 1 hour at 37°C. Serum sam-
ples, diluted 1:100 in 1.5% BSA, 0.1% Tween 20 in PBS,
were incubated for 3 hours at 37°C. The specific antibody
(Ab) response was then assessed by incubating with alka-
line phosphatase-conjugated mouse anti-human IgG1,
IgG2, IgG3 and IgG4 antibodies (Promega, Charbon-
nières, France) diluted 1:4000 in 1.5% BSA, 0.1% Tween
20 in PBS, for 1 hour at 37°C. The plates were washed
with 0.1% Tween 20 in PBS and the colorimetric reaction
was developed with p-nitrophenylphosphate (Sigma, St
Louis, MO) used as the substrate. Absorbance at 405 nm
was determined with a Labsystems Multiskan RC. Results
were expressed in optical density units after subtraction of
the values obtained with PBS and considered as positive
above 0.1 OD.
Statistical analysis
Comparisons between TB patients, BCG+ and/or BCG-
controls were performed using non parametric tests as
appropriate. Data were analyzed with StatView F-5.0 soft-
ware (1992–1998, SAS Institute Inc; California).
Results
Patients' characteristics
All subjects, after obtention of informed consent, were
tested negative for human immunodeficiency virus (HIV)
and none were on immunosuppressive therapy.
The median age of the TB patients (17 men and 5 women)
was 38 years (range 19–74). Most patients were Caucasian
(68.2%), and the others were African or Asian. Proof of
BCG vaccination was available for 8 of the 22 TB patients,
and the other 14 patients were born in countries in which
BCG vaccination is mandatory. Thus, it is likely that all
the TB patients had been vaccinated with BCG. Six of the
22 TB patients had a history of TB disease, with non opti-
mal treatment due to a lack of compliance in five patients
and infection with a multidrug-resistant strain in one
patient. The localization of the TB disease was pulmonary
(n = 14), extra-pulmonary (n = 6) or both (n = 2). Blood
samples were obtained before the initiation of specific
treatment for all patients.
BCG+ vaccinated subjects were divided into a BCG+ with-
out infection group (6 men and 3 women) and LTBI
group (4 men and 3 women) according to their responses
to ESAT-6. The median ages for these groups were 34 years
(range 19–73) and 28 years (range 19–50) respectively.
All individuals except one in each group were Caucasian
and the exceptions were of African origin. All BCG+ sub-
jects had been vaccinated with BCG during childhood. No
Mantoux test was performed in the BCG+ group.
The median age in the BCG- group (3 men and 4 women)
was 27 years (range 20–42). All individuals were Cauca-
sian. None of the BCG- subjects had a history of TB disease
or known contact with TB patients.
None of our subjects included in this study was anergic,
all of them have positive responses to mitogen used as
positive control in the different assays.
Specific responses in the lymphoproliferation assay
Lymphoproliferation assays were carried out for the 20 of
the 22 TB patients for who sufficient cells were available
and for nine BCG+ subjects including six BCG+ without
infection and three with LTBI (Figure 1). BCG- subjects
were not tested, as fresh cells were not available. Most TB
patients (19/20) and all (9/9) BCG+ subjects (LTBI and
without infection subjects) displayed positive prolifera-
tive responses with the PPD antigen. The median SI was
17.5 (range 1–125), 6.5 (range 3–20) and 26 (range 14–
180) for TB, BCG+ without infection and LTBI groups,
respectively.
A lower percentage of subjects from both groups dis-
played positive proliferative responses to the specificBMC Infectious Diseases 2007, 7:83 http://www.biomedcentral.com/1471-2334/7/83
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mycobacterial antigens. For Erp, 41% (9/22) of the TB,
17% (1/6) of the BCG+ without infection and 1/3 of the
BCG+ with LTBI groups displayed a positive proliferative
response, with an overall low median SI of 1 (range 1–
11), 1 (range 1–4) and 2 (range 1–9), respectively. For
ESAT-6, 59% (13/22) of the TB, none (0/6) of the BCG+
without infection and all (3/3) of the LTBI groups dis-
played a positive proliferative response, with an overall
median SI of 3 (range 1–37), 1 (range 1–2) and 6 (range
4–24), respectively. For Ag85B, 45% (10/22) of the TB,
33% (2/6) of the BCG+ without infection and 33% (1/3)
of the LTBI groups displayed a positive proliferative
response, with an overall low median SI of 2 (range 1–
17), 1.5 (range 1–4) and 1 (range 1–11), respectively. So
the responses to the 4 antigens appeared to be very similar
for the 3 groups of patients. However, although LTBI
patients responded to ESAT-6, BCG+  patients without
infection did not, as would be expected from the defini-
tion of the two groups. Finally, we observed no difference
in immune responses, as evaluated by lymphoprolifera-
tion assay, according to the site of TB infection.
IFN-γ responses detected by ELISpot assays depend on TB 
infection or disease status
The ELISpot IFN-γ assay was used to quantify antigen-spe-
cific CD4 T cells in 21 of the 22 TB patients, nine of the
BCG+ without infection group, seven of the LTBI and
seven of the BCG- controls. The ELISpot IFN-γ assay was
carried out with freshly prepared PBMC from TB patients
and BCG+ subjects and with frozen cells from BCG- indi-
viduals, after preliminary analysis to confirm that there
was no difference between the results obtained with
freshly prepared and frozen cells from BCG+ controls (n =
5): no significant difference was observed for Erp, ESAT-6,
Ag85B, PPD or PHA (p > 0.05) between the two cell prep-
arations.
We analyzed total PBMC and purified CD4 T cells for the
first five TB patients. Similar numbers of antigen-specific
T cells were obtained in the two assays. We therefore car-
ried out subsequent experiments with total PBMC, given
that the results accurately reflected CD4 T-cell responses
and the cutoff point was at least five IFN-γ SFC more than
in negative control wells. The results are summarized in
Figure 2.
BCG- controls displayed no IFN-γ cellular response to the
mycobacterial antigens Erp, ESAT-6, Ag85B and PPD as
expected, despite displaying normal responses to PHA.
TB patients developed IFN-γ-specific cellular responses,
directed against PPD and ESAT-6 in particular. A specific
T-cell response to PPD was detected in 86% (18/21) TB
patients, with a median positive frequency of375 SFC/106
PBMC (range 62–2000). Sixty-two percent (13/21) of TB
patients displayed T-cell responses to ESAT-6, with a
Proliferative responses to the specific mycobacterial antigens, PPD, Erp, ESAT-6 and Ag85B were evaluated in 3 groups: BCG+  subjects without infection, with latent TB infection (LTBI) and in TB patients (TB), measured by lymphoproliferation assay Figure 1
Proliferative responses to the specific mycobacterial antigens, PPD, Erp, ESAT-6 and Ag85B were evaluated in 3 groups: BCG+ 
subjects without infection, with latent TB infection (LTBI) and in TB patients (TB), measured by lymphoproliferation assay. A 
logarithmic scale is used and horizontal bars indicate positive values.
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Numbers of antigen-specific T cells in the 4 groups:non BCG-vaccinated controls (BCG-), BCG+ subjects without infection and  with latent TB infection (LTBI), and in TB patients (TB), measured by ELISpot IFN-γ assay after stimulation with PPD, Erp,  ESAT-6 and Ag85B Figure 2
Numbers of antigen-specific T cells in the 4 groups:non BCG-vaccinated controls (BCG-), BCG+ subjects without infection and 
with latent TB infection (LTBI), and in TB patients (TB), measured by ELISpot IFN-γ assay after stimulation with PPD, Erp, 
ESAT-6 and Ag85B. A logarithmic scale is used and horizontal bars indicate positive values.
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Cytokine productions (IFN-γ or ●, TNF-α or ▲ and IL-10 or ■) were represented for the 3 groups: BCG+ subjects without 
infection, with latent TB infection (LTBI) and in TB patients (TB).
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median positive frequency of280 SFC/106 PBMC range
53–799). Fewer TB patients displayed specific cellular
responses to Erp (38%, 8/21) and Ag85B (33%, 7/21),
with a median positive frequency of 80 SFC/106 PBMC
(range 50–191) and120 SFC/106 PBMC (range 73–200),
respectively.
LTBI subjects developed specific cellular responses,
directed against PPD, Erp and ESAT-6 in particular: 85.7%
(6/7) developed a PPD-specific T-cell responses (median
positive frequency434 SFC/106 PBMC (range 99–2000))
and 71% (5/7) developed Erp-specific T-cell responses
(median positive frequency 211 SFC/106 PBMC (range
118–2000)). ESAT-6-specific CD4 Th1 cell responses were
observed in 86% (6/7) of LTBI subjects (median positive
frequency 115 SFC/106 PBMC (range 73–310)), but only
43% (3/7) had Ag85B-specific CD4 Th1 responses
(median positive frequency112 SFC/106  PBMC (range
112–119)).
BCG+ subjects without infection developed specific cellu-
lar responses, directed only against PPD and Erp: 67% (6/
9) developed a PPD-specific T-cell responses (median
positive frequency 95 SFC/106 PBMC (range 53–350))
and 67% (6/9) developed Erp-specific T-cell responses
(median positive frequency142 SFC/106  PBMC (range
92–541)). Moreover, one out of 9 subjects had Ag85B-
specific CD4 Th1 responses (165 SFC/106  PBMC). As
expected, none of the BCG+ subjects without infection
gave ESAT-6-specific CD4 Th1 cell responses.
Numbers of PPD-specific T cells were similar for the three
groups of subjects (TB, BCG+ without infection group,
LTBI subjects) and higher than those BCG- group (p <
0.01). ESAT-6-specific T cells were similar in the TB and
LTBI groups, and significantly more numerous than in the
other groups (p ≤ 0.01). Only numbers of Erp-specific T
cells were significantly higher in BCG+ individuals with-
out infection or with LTBI than in TB patients (p ≤ 0.02).
This difference between LTBI and TB patients observed
after Erp stimulation was not found for PPD and ESAT-6
antigens.
Cytokine production
We evaluated the production of Th1/Th2 cytokines in a
subgroup of 13 TB patients and six BCG+ subjects (4 BCG+
individuals without infection and 2 with LTBI) for whom
cells were available. BCG-  subjects were not tested,
because cells were not available. The Th1 (IFN-γ, TNF-α,
IL-2) and Th2 (IL-4, IL-5, IL-10) cytokines present in the
supernatants of stimulated cells were quantified by flow
cytometry and the results are presented in Figure 3.
IFN-γ, TNF-α and IL-10 were detected after stimulation
with each of the antigens tested: Erp, ESAT-6, Ag85B and
PPD. By contrast, IL-2, IL-4 and IL-5 were not detected fol-
lowing stimulation with any of the antigens (data not
shown).
In TB patients, IFN-γ, TNF-α and IL-10 productions were
detected after stimulation with PPD (median 325, range
22–1389; median 179, range 0–1178; median 12, range
0–182 respectively), ESAT-6 (median 13, range 0–4597;
median 179, range 0–1679; median 65, range 0–191
respectively) and Erp (median 11, range 0–245; median
652, range 0–1961; median 228, range 0–1662 respec-
tively).
In the LTBI group, IFN-γ and TNF-α productions were also
detected after stimulation with PPD, Erp and with ESAT-6
stimulation for the 2 patients tested. IL-10 production was
very low.
In three of the four BCG+ individuals without infection,
IFN-γ and TNF-α production were mainly detected only
after PPD stimulation. No IFN-γ or TNF-α production was
detected after stimulation with ESAT-6. IL-10 and TNF-α
were detected after Erp stimulation.
Poor production of cytokine was detected after stimula-
tion with Ag85B in the 3 groups of patients.
Humoral responses
We tested the available serum samples from the individu-
als included in the study (15 TB patients, 4 BCG+ subjects
without infection and 3 LTBI subjects) for the presence of
Subtypes of IgG were represented in column bar after Erp,  ESAT-6 and Ag85B stimulation in the 4 groups: non BCG- vaccinated controls (BCG-), BCG+ subjects without infection,  with latent TB infection (LTBI) and in TB patients (TB) in the  order: IgG1, IgG2, IgG3, IgG4 Figure 4
Subtypes of IgG were represented in column bar after Erp, 
ESAT-6 and Ag85B stimulation in the 4 groups: non BCG-
vaccinated controls (BCG-), BCG+ subjects without infection, 
with latent TB infection (LTBI) and in TB patients (TB) in the 
order: IgG1, IgG2, IgG3, IgG4.
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subclasses of IgG antibodies against Erp, ESAT-6 and
Ag85B (Figure 4). Specific antibody levels were highly het-
erogeneous in all groups, resulting in high standard devi-
ations.
For the BCG- group, levels of specific IgG subclasses were
below this threshold for all antigens.
TB patients developed specific IgG1 (n = 8) and IgG2 (n =
7) against Erp and IgG1 (n = 11) and IgG3 (n = 2) against
ESAT-6 (Figure 4).
All LTBI individuals produced at least three of IgG sub-
types IgG1, IgG2, IgG3 and IgG4 after Erp or ESAT-6 stim-
ulation. In the BCG+ group, no IgG were detected against
Erp, ESAT-6.
We observed high production of IgG3 against Erp in LTBI
subjects but IgG3 was not produced by TB patients or by
BCG+  individuals without infection. The profile of
responses to Erp and ESAT-6 antigens was consistent with
the findings of the assays evaluating cellular immunity.
Discussion
We studied cellular and humoral immune responses to
Erp, a recently identified M. tuberculosis protein and three
mycobacterial antigens: PPD, ESAT-6 and Ag85B.
In our study, most TB patients responded to ESAT6. This
is consistent with published studies [9,33,34] In which 55
to 95% of TB patients displayed an ESAT-6-specific Th1
response, as evaluated by lymphoproliferation assays or
by determining IFN-γ concentration in the supernatant of
stimulated cells [22,33]. ESAT-6, a RD-1-encoded M.
tuberculosis-specific antigen, is an accurate marker of M.
tuberculosis infection; it discriminates against BCG because
the RD-1 region is deleted from such strains [20-
22,24,35]. It can therefore be used to differentiate
between individuals with and without TB infection,
regardless of BCG vaccination status [36-39]. Neverthe-
less, 43% of BCG-vaccinated subjects responded to ESAT-
6 in our study. There are several possible explanations for
this result: exposure to M. tuberculosis is not implausible
because 12.5% of the participants originated from Africa
or Asia and 31% were hospital workers. Thus, these find-
ings may be the consequence of cases of latent TB infec-
tion despite no reported previous TB contact or exposure
to environmental mycobacteria in France or during visits
to countries in which these bacteria are highly prevalent.
These observations led us to distinguish between BCG+
individuals without infection (ESAT-6-) and with LTBI
(ESAT-6+) in our analysis.
We also analyzed immune responses to Ag85B, a myco-
bacterial antigen involved in the final stages of cell wall
synthesis [26,40,41]. Subjects in all groups displayed
weak humoral and cellular immune responses after
Ag85B antigen stimulation, consistent with the findings
of previous studies [36,42-44].
Erp is an exported protein encoding a cell-surface compo-
nent [11,13,14], and is present in all strains of mycobac-
teria, including BCG strains. Erp is crucial for the survival
and multiplication of mycobacteria [10,15]. In this study,
we demonstrated that Erp induced cellular and humoral
responses in BCG+ subjects without infection, in LTBI sub-
jects and in TB patients. The Erp antigen has previously
only been studied in macrophage cell lines and in vivo in
mouse models. This study is the first to evaluate human
cellular and humoral immune responses to Erp in TB
patients and in individuals vaccinated and not vaccinated
with BCG. We show that LTBI subjects had more Erp-spe-
cific IFN-γ-producing cells than TB patients and Erp-spe-
cific IgG3 were present only in infected but non-ill BCG+
subjects corresponding to latent TB infection. These
results are consistent with previous findings concerning
the production of IFN-γ by activated T cells, which is
required for the regulation of isotype switching during B-
cell development [45-47]. IFN-γ regulates the isotype spe-
cificity of switching and can induce switching to IgG3
[47]. Furthermore, the orientation of the response toward
the IgG3 subclass is surface antigen-specific [48-50]. Erp is
a surface antigen, whereas ESAT-6 is a secreted antigen,
and this explains the detection of IgG3 after Erp stimula-
tion. An association has been found between antibody
isotype, cytokine profile and pathogenesis in some infec-
tious diseases, including leprosy and malaria, but never in
tuberculosis [51-54]. Moreover, T cell-derived cytokines,
such as IL-10, have been reported to be involved in the
regulation of switch factors for IgG3 [55]. The significance
of IgG3 specificity in infectious diseases remains unclear.
Functionally, IgG3 is considered to be the most effective
subclass for activating the complement pathway and
mediates cell lysis by monocytes and Fc receptor-bearing
lymphocytes. In a study of severe malaria, Sarthou et al.
demonstrated that only P. falciparum-specific IgG3 levels
were positively correlated with survival [56]. So, in light of
published data and our results, IgG3 against Erp could be
used as a surrogate marker of protection against TB. More-
over, Erp, an exported surface antigen but not a secreted
antigen, was not directly associated with virulence but
may be implicated in latency, as in our study. This antigen
is potentially useful for the diagnosis of tuberculosis dis-
ease versus latent infection and this possibility should be
tested in a very large series of patients.
Conclusion
Our results show that Erp induces T-cell or humoral
responses in TB patients and in BCG+ subjects without
infection and with LTBI. The responses against this anti-BMC Infectious Diseases 2007, 7:83 http://www.biomedcentral.com/1471-2334/7/83
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gen, unlike those against PPD and ESAT-6, are higher in
LTBI individuals than in TB patients. The response to Erp
may therefore be useful for the diagnosis of TB discrimi-
nating between disease and infection with M. tuberculosis.
The choice of antituberculous therapy and of therapy
duration depends on this distinction between infection
and disease. This interesting possibility arising from our
pilot study needs to be tested in studies with a large
number of patients to confirm the possible contribution
of Erp to the diagnosis of latent TB infection.
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